EDSA
Edesa Biotech, Inc.
Next earnings Aug 6, 2026 · consensus $-0.64 EPS
Last earnings -4.1% on 2026-05-14
$8.19
▲ +9.64%$8.19▲ +309.50%
over 1Y
L $0.80EODHDH $18.28
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+9.6%
1W+20.3%
1M+2.8%
3M+40.7%
YTD+446.0%
1Y+309.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.15x); but revenue fell -100.0% YoY.
Revenue (FY2021) $0.00 · FY2021
Edesa Biotech, Inc. shows $0.00 in FY2021 revenue (-100.0% YoY), and -57.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.7M | -$18.4M | -$9.22M | -$7.01M | -$7.91M |
| Net income | -$13.3M | -$17.5M | -$8.37M | -$6.17M | -$7.19M |
| Diluted EPS | -$1.10 | — | — | — | — |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$57.5M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-10.5%
FCF yield-10.7%
Quality & risk
ROIC (est.)-50.2%
Free cash flow-$7.32M
Total debt—
Net cash$10.8M
Altman Z-Score14.52 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+140.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗DFiling2026-06-26open ↗SCHEDULE 13GFiling2026-06-18open ↗SCHEDULE 13D/AFiling2026-06-16open ↗4Period ending 2026-06-162026-06-16open ↗8-KPeriod ending 2026-06-102026-06-11open ↗8-KPeriod ending 2026-06-052026-06-05open ↗4Period ending 2026-06-012026-06-01open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗4Period ending 2026-05-272026-05-29open ↗
Frequently asked
- Is Edesa Biotech, Inc. (EDSA) a buy?
- EDSA currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.15x); but revenue fell -100.0% YoY.
- What is Edesa Biotech, Inc.'s quality score?
- EDSA scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001540159, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:48:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.